MOPP regimen prednisone

Nitrogen mustard is clinically used for the treatment of lymphomas and some forms of lung cancer. The major indication for mechlorethamine is Hodgkin s disease as a part of the MOPP regimen (mechlorethamine + vincristine (oncovin) + procarbazine + prednisone). The usual dose consists of 6 mg/m2 on days 1 and 8. This drug has pronounced hematological toxicity (myelo-suppression). 

The chemotherapy of advanced Hodgkin s disease is one of the best examples of successful combination chemotherapy. Combination therapy with the MOPP regimen (mechlorethamine, Oncovin [vincristine sulfate], procarbazine, prednisone), alternating with ABVD (Adriamycin [doxorubicin hydrochloride], bleomycin, vinblastine, dacarbazine), has resulted in cure rates of 50 to 60%. 

The major indication for mechlorethamine is Hodgkin s disease the drug is given in the MOPP regimen (mechlorethamine, vincristine, procarbazine, prednisone see Chapter 55). Other less reactive nitrogen mustards are now preferred for the treatment of non-Hodgkin s lymphomas, leukemias, and various solid tumors. 

Therapeutic applications Mechlorethamine is used primarily in the treatment of Hodgkin s disease as part of the MOPP regimen (Mechlorethamine, Oncovin, Prednisone, Procarbazine), and is also useful in the treatment of some solid tumors. 

Procarbazine, an antineoplastic agent (2 to 4 mg/kg/day for the first week) in combination with other antineoplastic agents (MOPP regimen—nitrogen mustard, vincristine, procarbazine, prednisone), is indicated in the treatment of stage III and IV Hodgkin s disease. Procarbazine inhibits the synthesis of protein RNA and DNA (see also Figure 15). 

A. Glucocorticoids Prednisone is the most commonly used glucocorticoid in cancer chemotherapy. The steroid has applications in dmg regimens for acute and chronic lymphocytic leukemia. Hodgkin s disease (MOPP regimen), and other lymphomas. Toxicity is described in Chapter 39. 

More recently, a German study compared a dose-escalated regimen of BEACOPP (with filgrastim support) with standard-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, gemcitabine (BEACOPP) and COPP alternating with ABVD (C—cyclophosphamide instead of mechlorethamine for MOPP).18 The escalated BEACOPP was... 

Procarbazine is an alkylating agent that is used in the treatment of Hodgkin s disease in regimens such as MOPP (chlormethine (mechlorethamine), vincristine (Oncovin), procarbazine, and prednisolone) and BEACOPP (bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine, procarbazine, and prednisone) (1). It is also used to treat glioblastoma multiforme. 

One of the initial combination chemotherapy regimens introduced in the early 1960s that was shown to produce cures in advanced Hodgkin s disease was the MOPP (mechlorethamine, vincristine [Oncovin], procarbazine, and prednisone) regimen (see Table 129-6)P MOPP chemotherapy has been a mainstay of treatment for patients with stage III and IV advanced Hodgkin s disease. According... 

Mechlorethamine HCl (Mustargen) was formerly used primarily in the combination chemotherapy regimen MOPP (mechlorethamine, vincristine [Oncovin], procarbazine, and prednisone) in patients with Hodgkin s disease. It is given by intravenous bolus administration in doses of 6 mg/m on days 1 and 8 of the 28-day cycles of each course of treatment. It has been largely replaced by cyclophosphamide, melphalan, and other more stable alkylating agents. It also is used topically for treatment of cutaneous T-cell lymphoma as a solution that is rapidly mixed and applied to affected areas of skin. 

Registered trademark of Merck. Used in combination chemotherapeutic regimens, i.e., MOPP mustine (Mustargen), vincristine (Oncovin),procarbazine,prednisone (not to be confused with other MOPP and NBC protection clothing). 

---